FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112596513> ?p ?o ?g. }

• W2112596513 endingPage "887" @default.
• W2112596513 startingPage "879" @default.
• W2112596513 abstract "Abstract Preclinical, epidemiologic, and prior clinical trial data suggest that green tea catechins (GTC) may reduce prostate cancer risk. We conducted a placebo-controlled, randomized clinical trial of Polyphenon E (PolyE), a proprietary mixture of GTCs, containing 400 mg (−)-epigallocatechin-3-gallate (EGCG) per day, in 97 men with high-grade prostatic intraepithelial neoplasia (HGPIN) and/or atypical small acinar proliferation (ASAP). The primary study endpoint was a comparison of the cumulative one-year prostate cancer rates on the two study arms. No differences in the number of prostate cancer cases were observed: 5 of 49 (PolyE) versus 9 of 48 (placebo), P = 0.25. A secondary endpoint comparing the cumulative rate of prostate cancer plus ASAP among men with HGPIN without ASAP at baseline, revealed a decrease in this composite endpoint: 3 of 26 (PolyE) versus 10 of 25 (placebo), P &lt; 0.024. This finding was driven by a decrease in ASAP diagnoses on the Poly E (0/26) compared with the placebo arm (5/25). A decrease in serum prostate-specific antigen (PSA) was observed on the PolyE arm [−0.87 ng/mL; 95% confidence intervals (CI), −1.66 to −0.09]. Adverse events related to the study agent did not significantly differ between the two study groups. Daily intake of a standardized, decaffeinated catechin mixture containing 400 mg EGCG per day for 1 year accumulated in plasma and was well tolerated but did not reduce the likelihood of prostate cancer in men with baseline HGPIN or ASAP. Cancer Prev Res; 8(10); 879–87. ©2015 AACR." @default.
• W2112596513 created "2016-06-24" @default.
• W2112596513 creator A5000121125 @default.
• W2112596513 creator A5006649365 @default.
• W2112596513 creator A5008741320 @default.
• W2112596513 creator A5014436324 @default.
• W2112596513 creator A5025379817 @default.
• W2112596513 creator A5027131819 @default.
• W2112596513 creator A5027819464 @default.
• W2112596513 creator A5030934788 @default.
• W2112596513 creator A5033353421 @default.
• W2112596513 creator A5035265739 @default.
• W2112596513 creator A5045403568 @default.
• W2112596513 creator A5053264588 @default.
• W2112596513 creator A5055870934 @default.
• W2112596513 creator A5055925608 @default.
• W2112596513 creator A5056350826 @default.
• W2112596513 creator A5061628135 @default.
• W2112596513 creator A5065882417 @default.
• W2112596513 creator A5081874318 @default.
• W2112596513 creator A5090472542 @default.
• W2112596513 creator A5090773483 @default.
• W2112596513 creator A5091519536 @default.
• W2112596513 date "2015-10-01" @default.
• W2112596513 modified "2023-10-15" @default.
• W2112596513 title "Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention" @default.
• W2112596513 cites W1489730199 @default.
• W2112596513 cites W1517442176 @default.
• W2112596513 cites W155804842 @default.
• W2112596513 cites W1868067763 @default.
• W2112596513 cites W1872782065 @default.
• W2112596513 cites W1909055669 @default.
• W2112596513 cites W1973203637 @default.
• W2112596513 cites W1979008650 @default.
• W2112596513 cites W1988775004 @default.
• W2112596513 cites W1988913944 @default.
• W2112596513 cites W1992759183 @default.
• W2112596513 cites W1997116070 @default.
• W2112596513 cites W1998207473 @default.
• W2112596513 cites W1999223207 @default.
• W2112596513 cites W2001655892 @default.
• W2112596513 cites W2002384741 @default.
• W2112596513 cites W2007824082 @default.
• W2112596513 cites W2016313181 @default.
• W2112596513 cites W2017359766 @default.
• W2112596513 cites W2025445728 @default.
• W2112596513 cites W2028491514 @default.
• W2112596513 cites W2039250830 @default.
• W2112596513 cites W2039365176 @default.
• W2112596513 cites W2047353255 @default.
• W2112596513 cites W2047416003 @default.
• W2112596513 cites W2053779887 @default.
• W2112596513 cites W2067051165 @default.
• W2112596513 cites W2073446165 @default.
• W2112596513 cites W2075245880 @default.
• W2112596513 cites W2077524986 @default.
• W2112596513 cites W2077669101 @default.
• W2112596513 cites W2078152002 @default.
• W2112596513 cites W2078939459 @default.
• W2112596513 cites W2084956200 @default.
• W2112596513 cites W2094183836 @default.
• W2112596513 cites W2103498170 @default.
• W2112596513 cites W2105408725 @default.
• W2112596513 cites W2113061094 @default.
• W2112596513 cites W2114234907 @default.
• W2112596513 cites W2117792530 @default.
• W2112596513 cites W2117900168 @default.
• W2112596513 cites W2125110063 @default.
• W2112596513 cites W2125242482 @default.
• W2112596513 cites W2125565767 @default.
• W2112596513 cites W2127203984 @default.
• W2112596513 cites W2128536507 @default.
• W2112596513 cites W2130791546 @default.
• W2112596513 cites W2137270941 @default.
• W2112596513 cites W2139698414 @default.
• W2112596513 cites W2142285790 @default.
• W2112596513 cites W2147958963 @default.
• W2112596513 cites W2152835156 @default.
• W2112596513 cites W2155530804 @default.
• W2112596513 cites W2156153418 @default.
• W2112596513 cites W2160209118 @default.
• W2112596513 cites W2167185749 @default.
• W2112596513 cites W2168740776 @default.
• W2112596513 cites W2170714849 @default.
• W2112596513 cites W2171912445 @default.
• W2112596513 cites W2887478824 @default.
• W2112596513 cites W3135529189 @default.
• W2112596513 cites W4231090826 @default.
• W2112596513 cites W4362207783 @default.
• W2112596513 doi "https://doi.org/10.1158/1940-6207.capr-14-0324" @default.
• W2112596513 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4596745" @default.
• W2112596513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25873370" @default.
• W2112596513 hasPublicationYear "2015" @default.
• W2112596513 type Work @default.
• W2112596513 sameAs 2112596513 @default.
• W2112596513 citedByCount "100" @default.
• W2112596513 countsByYear W21125965132015 @default.
• W2112596513 countsByYear W21125965132016 @default.

• next